Community post

Matt McEnany (U Colorado) and Kevin Outterson (Boston University, Founder and Executive Director of CARB-X) published a new paper on evaluating Germany's new antimicrobial reimbursement reforms. They compare these reforms to delinked pull incentives (where governments pay drug companies after they make their drug, independently of how much their drug is sold).